Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.86
BMY's Cash-to-Debt is ranked lower than
62% of the 860 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. BMY: 0.86 )
Ranked among companies with meaningful Cash-to-Debt only.
BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36  Med: 0.97 Max: 3.88
Current: 0.86
0.36
3.88
Equity-to-Asset 0.35
BMY's Equity-to-Asset is ranked lower than
75% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BMY: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
BMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.45 Max: 0.62
Current: 0.35
0.33
0.62
Debt-to-Equity 0.68
BMY's Debt-to-Equity is ranked lower than
68% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. BMY: 0.68 )
Ranked among companies with meaningful Debt-to-Equity only.
BMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09  Med: 0.38 Max: 1.01
Current: 0.68
0.09
1.01
Debt-to-EBITDA 1.30
BMY's Debt-to-EBITDA is ranked higher than
60% of the 511 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. BMY: 1.30 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BMY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.71  Med: 1.22 Max: 2.57
Current: 1.3
0.71
2.57
Interest Coverage 18.43
BMY's Interest Coverage is ranked lower than
63% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 127.83 vs. BMY: 18.43 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 10.27  Med: 17 Max: 45.84
Current: 18.43
10.27
45.84
Piotroski F-Score: 6
Altman Z-Score: 5.68
Beneish M-Score: -3.27
WACC vs ROIC
8.75%
2.66%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.39
BMY's Operating Margin % is ranked higher than
83% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.71 vs. BMY: 17.39 )
Ranked among companies with meaningful Operating Margin % only.
BMY' s Operating Margin % Range Over the Past 10 Years
Min: 11.41  Med: 21.37 Max: 31.29
Current: 17.39
11.41
31.29
Net Margin % 4.85
BMY's Net Margin % is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. BMY: 4.85 )
Ranked among companies with meaningful Net Margin % only.
BMY' s Net Margin % Range Over the Past 10 Years
Min: 4.85  Med: 15.78 Max: 56.42
Current: 4.85
4.85
56.42
ROE % 7.01
BMY's ROE % is ranked higher than
91% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. BMY: 7.01 )
Ranked among companies with meaningful ROE % only.
BMY' s ROE % Range Over the Past 10 Years
Min: 7.01  Med: 19.06 Max: 78.36
Current: 7.01
7.01
78.36
ROA % 3.00
BMY's ROA % is ranked higher than
84% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. BMY: 3.00 )
Ranked among companies with meaningful ROA % only.
BMY' s ROA % Range Over the Past 10 Years
Min: 2.99  Med: 8.44 Max: 35.08
Current: 3
2.99
35.08
ROC (Joel Greenblatt) % 105.38
BMY's ROC (Joel Greenblatt) % is ranked higher than
96% of the 850 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.46 vs. BMY: 105.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 45.71  Med: 94.31 Max: 155.17
Current: 105.38
45.71
155.17
3-Year Revenue Growth Rate 9.80
BMY's 3-Year Revenue Growth Rate is ranked higher than
51% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BMY: 9.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.4  Med: 3.1 Max: 11.8
Current: 9.8
-8.4
11.8
3-Year EBITDA Growth Rate 26.50
BMY's 3-Year EBITDA Growth Rate is ranked higher than
68% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. BMY: 26.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26  Med: 7.6 Max: 26.5
Current: 26.5
-26
26.5
3-Year EPS without NRI Growth Rate -20.20
BMY's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. BMY: -20.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 5.4 Max: 30.7
Current: -20.2
-22.9
30.7
GuruFocus has detected 3 Warning Signs with Bristol-Myers Squibb Company BMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMY's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

BMY Guru Trades in Q1 2017

Joel Greenblatt 10,061 sh (New)
PRIMECAP Management 1,772,900 sh (New)
Steven Cohen 152,500 sh (New)
Ray Dalio 96,670 sh (New)
Frank Sands 17,124 sh (New)
Jim Simons 6,468,000 sh (+983.42%)
Jeff Auxier 7,393 sh (+57.53%)
Dodge & Cox 29,120,190 sh (+29.23%)
T Rowe Price Equity Income Fund 3,750,000 sh (+20.00%)
Manning & Napier Advisors, Inc 3,236,578 sh (+5.76%)
Vanguard Health Care Fund 52,795,017 sh (+2.83%)
Ken Fisher 666,264 sh (+1.92%)
Mairs and Power 344,280 sh (+1.01%)
First Eagle Investment 11,529 sh (unchged)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 721,457 sh (unchged)
David Tepper Sold Out
Jeremy Grantham Sold Out
Ronald Muhlenkamp 178,201 sh (-0.42%)
Pioneer Investments 108,348 sh (-1.95%)
Mario Gabelli 513,047 sh (-2.03%)
Murray Stahl 48,607 sh (-7.58%)
Paul Tudor Jones 21,701 sh (-8.73%)
Signature Select Canadian Fund 118,750 sh (-25.99%)
Jana Partners 716,389 sh (-81.50%)
» More
Q2 2017

BMY Guru Trades in Q2 2017

Louis Moore Bacon 110,820 sh (New)
Caxton Associates 6,600 sh (New)
Joel Greenblatt 87,459 sh (+769.29%)
Paul Tudor Jones 82,386 sh (+279.64%)
PRIMECAP Management 6,315,000 sh (+256.20%)
Jim Simons 13,488,200 sh (+108.54%)
Ray Dalio 131,064 sh (+35.58%)
Vanguard Health Care Fund 53,643,117 sh (+1.61%)
Dodge & Cox 29,579,461 sh (+1.58%)
Murray Stahl 48,990 sh (+0.79%)
Tom Gayner 10,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Jana Partners Sold Out
Ronald Muhlenkamp 177,974 sh (-0.13%)
Mairs and Power 343,043 sh (-0.36%)
First Eagle Investment 11,329 sh (-1.73%)
Frank Sands 16,774 sh (-2.04%)
T Rowe Price Equity Income Fund 3,670,300 sh (-2.13%)
Mario Gabelli 466,082 sh (-9.15%)
Jeff Auxier 6,393 sh (-13.53%)
Ken Fisher 507,027 sh (-23.90%)
Pioneer Investments 80,594 sh (-25.62%)
Kahn Brothers 19,583 sh (-31.49%)
Steven Cohen 100,000 sh (-34.43%)
Manning & Napier Advisors, Inc 2,034,602 sh (-37.14%)
Eaton Vance Worldwide Health Sciences Fund 645,201 sh (-10.57%)
» More
Q3 2017

BMY Guru Trades in Q3 2017

Pioneer Investments 1,338,444 sh (+1560.72%)
First Eagle Investment 49,229 sh (+334.54%)
Paul Tudor Jones 124,964 sh (+51.68%)
Joel Greenblatt 121,594 sh (+39.03%)
Louis Moore Bacon 142,025 sh (+28.16%)
Frank Sands 17,324 sh (+3.28%)
PRIMECAP Management 6,374,900 sh (+0.95%)
Mario Gabelli 467,867 sh (+0.38%)
Murray Stahl 49,015 sh (+0.05%)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 6,393 sh (unchged)
Ray Dalio Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 177,169 sh (-0.45%)
Ken Fisher 504,493 sh (-0.50%)
Mairs and Power 339,845 sh (-0.93%)
Dodge & Cox 29,054,961 sh (-1.77%)
Kahn Brothers 19,050 sh (-2.72%)
Vanguard Health Care Fund 50,693,892 sh (-5.50%)
Manning & Napier Advisors, Inc 1,884,716 sh (-7.37%)
T Rowe Price Equity Income Fund 3,165,000 sh (-13.77%)
Jim Simons 10,846,600 sh (-19.58%)
Steven Cohen 75,000 sh (-25.00%)
Signature Select Canadian Fund 71,350 sh (-39.92%)
Eaton Vance Worldwide Health Sciences Fund 597,663 sh (-7.37%)
» More
Q4 2017

BMY Guru Trades in Q4 2017

Jeremy Grantham 10,700 sh (New)
Pioneer Investments 2,797,167 sh (+108.99%)
Steven Cohen 115,000 sh (+53.33%)
Louis Moore Bacon 192,140 sh (+35.29%)
Jim Simons 14,302,900 sh (+31.87%)
Joel Greenblatt 154,793 sh (+27.30%)
Ken Fisher 582,213 sh (+15.41%)
PRIMECAP Management 6,557,578 sh (+2.87%)
Dodge & Cox 29,106,111 sh (+0.18%)
Kahn Brothers 19,050 sh (unchged)
First Eagle Investment 49,229 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 6,393 sh (unchged)
Frank Sands Sold Out
Murray Stahl 48,915 sh (-0.20%)
Ronald Muhlenkamp 174,575 sh (-1.46%)
Mairs and Power 332,592 sh (-2.13%)
T Rowe Price Equity Income Fund 3,040,000 sh (-3.95%)
Vanguard Health Care Fund 48,534,812 sh (-4.26%)
Mario Gabelli 408,602 sh (-12.67%)
Paul Tudor Jones 29,786 sh (-76.16%)
Eaton Vance Worldwide Health Sciences Fund 565,824 sh (-5.33%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-12-31 Reduce -4.26%0.3%$59.94 - $65.35 $ 67.959%48,534,812
Dodge & Cox 2017-12-31 Add 0.18%$59.94 - $65.35 $ 67.959%29,106,111
T Rowe Price Equity Income Fund 2017-12-31 Reduce -3.95%0.04%$59.94 - $65.35 $ 67.959%3,040,000
Ken Fisher 2017-12-31 Add 15.41%0.01%$59.94 - $65.35 $ 67.959%582,213
Mario Gabelli 2017-12-31 Reduce -12.67%0.02%$59.94 - $65.35 $ 67.959%408,602
Ronald Muhlenkamp 2017-12-31 Reduce -1.46%0.05%$59.94 - $65.35 $ 67.959%174,575
Joel Greenblatt 2017-12-31 Add 27.30%0.03%$59.94 - $65.35 $ 67.959%154,793
Vanguard Health Care Fund 2017-09-30 Reduce -5.50%0.35%$54.24 - $63.74 $ 67.9516%50,693,892
Dodge & Cox 2017-09-30 Reduce -1.77%0.02%$54.24 - $63.74 $ 67.9516%29,054,961
T Rowe Price Equity Income Fund 2017-09-30 Reduce -13.77%0.13%$54.24 - $63.74 $ 67.9516%3,165,000
Ken Fisher 2017-09-30 Reduce -0.50%$54.24 - $63.74 $ 67.9516%504,493
Mario Gabelli 2017-09-30 Add 0.38%$54.24 - $63.74 $ 67.9516%467,867
Ronald Muhlenkamp 2017-09-30 Reduce -0.45%0.01%$54.24 - $63.74 $ 67.9516%177,169
Joel Greenblatt 2017-09-30 Add 39.03%0.03%$54.24 - $63.74 $ 67.9516%121,594
First Eagle Investment 2017-09-30 Add 334.54%0.01%$54.24 - $63.74 $ 67.9516%49,229
Kahn Brothers 2017-09-30 Reduce -2.72%$54.24 - $63.74 $ 67.9516%19,050
Vanguard Health Care Fund 2017-06-30 Add 1.61%0.1%$51.66 - $57.33 $ 67.9525%53,643,117
Dodge & Cox 2017-06-30 Add 1.58%0.02%$51.66 - $57.33 $ 67.9525%29,579,461
T Rowe Price Equity Income Fund 2017-06-30 Reduce -2.13%0.02%$51.66 - $57.33 $ 67.9525%3,670,300
Ken Fisher 2017-06-30 Reduce -23.90%0.01%$51.66 - $57.33 $ 67.9525%507,027
Mario Gabelli 2017-06-30 Reduce -9.15%0.02%$51.66 - $57.33 $ 67.9525%466,082
Ronald Muhlenkamp 2017-06-30 Reduce -0.13%$51.66 - $57.33 $ 67.9525%177,974
Joel Greenblatt 2017-06-30 Add 769.29%0.06%$51.66 - $57.33 $ 67.9525%87,459
Kahn Brothers 2017-06-30 Reduce -31.49%0.09%$51.66 - $57.33 $ 67.9525%19,583
First Eagle Investment 2017-06-30 Reduce -1.73%$51.66 - $57.33 $ 67.9525%11,329
Vanguard Health Care Fund 2017-03-31 Add 2.83%0.18%$46.82 - $60.13 $ 67.9524%52,795,017
Dodge & Cox 2017-03-31 Add 29.23%0.31%$46.82 - $60.13 $ 67.9524%29,120,190
T Rowe Price Equity Income Fund 2017-03-31 Add 20.00%0.16%$46.82 - $60.13 $ 67.9524%3,750,000
Ken Fisher 2017-03-31 Add 1.92%$46.82 - $60.13 $ 67.9524%666,264
Mario Gabelli 2017-03-31 Reduce -2.03%$46.82 - $60.13 $ 67.9524%513,047
Ronald Muhlenkamp 2017-03-31 Reduce -0.42%0.01%$46.82 - $60.13 $ 67.9524%178,201
Joel Greenblatt 2017-03-31 New Buy0.01%$46.82 - $60.13 $ 67.9524%10,061
David Tepper 2017-03-31 Sold Out 0.39%$46.82 - $60.13 $ 67.9524%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP.PFD1306.550.15$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XPAR:SAN, XTER:BAYA, NYSE:LLY, LSE:GSK, LSE:AZN, NYSE:MRK, TSE:4519, TSE:4503, TSE:4578, TSE:4568, HKSE:01093, NYSE:ABBV, XSWX:ROG, TSE:4528, TSE:4151, MIL:REC, BOM:500087, BOM:500302, XSWX:NOVN, SHSE:600436 » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Headquarter Location:USA
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments namely Pharmaceuticals and Nutritionals.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Guru Investment Theses on Bristol-Myers Squibb Company

Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company - Feb 13, 2017

Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players (AstraZeneca, the other) that will have an opportunity to ultimately come out on top given its strategy of combining two immune-therapeutics. We intend to follow the situation closely while looking for a more appropriate time to potentially get back into the investment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Dodge & Cox Comments on Bristol-Myers Squibb - Feb 01, 2017

Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis.



In 2016, one of Bristol-Myers’ lead immuno-oncology trials (CheckMate-026) failed and its stock price declined significantly. We think this is a short-term setback, and believe the company’s immuno-oncology business is particularly attractive with its strong pipeline of other drugs, significant growth potential, and reasonable valuation at 20 times forward earnings. After weighing the risks versus the long-term opportunities, we initiated a position in Bristol-Myers, which accounted for 1.3% of the Fund on December 31.





From Dodge & Cox's Stock Fund 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Co. - Oct 25, 2016

Bristol-Myers Squibb Company (NYSE:BMY) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb - May 23, 2016

After watching and following Bristol-Myers Squibb (NYSE:BMY) for the better part of the last three years we used the weakness in the stock created by the sell-off in the biotech sector to finally initiate a small to medium size position. Bristol specializes in small molecule drugs known as biologics, which are harder for the generic drug companies to replicate, and we are particularly excited about its lead immuno-oncology asset, Opdivo which has shown incredible promise in the treatment of lung cancer, while growing 10-20% month over month since its approval in 2015. Based on our belief in the effectiveness of the PD-1 class drugs, we think there is a high likelihood that Bristol will be able to gain approvals and expand the usage of Opdivo in other types of cancers (melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and could potentially change the paradigm of cancer’s treatment worldwide.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Company - May 06, 2016

After initiating a position in Bristol-Myers Squibb Company (NYSE:BMY), we increased our conviction in BMY’s stature as one of the premier names in all of biotech/pharma, deserving of its high multiple. Confidence comes from the performance of its lead immune-oncology asset, Opdivo that has captured 80–85% market share versus Merck’s competitive asset Keytruda, while growing 10–20% month over month. Given the frenetic pace of growth, we expect Opdivo to easily beat 2016’s $2.1 billion Consensus sales number. Looking past 2016, we expect this trend to continue as Bristol launches and/or expands usage of Opdivo in a variety of cancers (lung, melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and helps change the paradigm of cancer’s treatment worldwide.





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Market Trends Toward New Normal in Container Store, Signature Bank, Bridgepoint Education, Skechers U.S.A., Bristol-Myers Squibb, and Mastercard — Emerging Consolidated Expectations, Analyst Ratings
Wall Street Is in the Green TripAdvisor up on revenue beat
U.S. stocks are in the green amid a recent report of inflation that pushed the stock market to a fifth day of gains. Further, the interest rate of the 10-year bond hit a four-year high. Read more...
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company (NYSE: BMY) To Contact Brower Piven Before The Lead Plaintiff Deadline
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018
Wall Street Wants Details About Lung Cancer Drug Bristol-Myers releases strong fourth-quarter earnings but falls short on allaying concerns of drug's unknowns
Wall Street analysts are pressuring Bristol-Myers Squibb Co. (NYSE:BMY) to provide more specifics on next-steps in the development of a breakthrough lung cancer drug. Read more...
World Stock Markets in Red Bristol-Myers beats estimates
U.S. stocks continued to decline in premarket trading on Monday, extending losses from last week. Read more...
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time
Building a Circle of Competency My journey of building a circle of competency in the pharmaceutical business
In my previous article I shared my favorite quotes from Li Lu on the subject of circle of competency. While those quotes are great, they won’t have any practical value unless we can actually put them into practice. Today I’ll share my journey of building a circle of competency (could very well be a circle of incompetence) in the pharmaceutical business. Read more...

Ratios

vs
industry
vs
history
PE Ratio 113.25
BMY's PE Ratio is ranked higher than
53% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.21 vs. BMY: 113.25 )
Ranked among companies with meaningful PE Ratio only.
BMY' s PE Ratio Range Over the Past 10 Years
Min: 4.09  Med: 24.24 Max: 114.93
Current: 113.25
4.09
114.93
Forward PE Ratio 21.23
BMY's Forward PE Ratio is ranked lower than
58% of the 73 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.67 vs. BMY: 21.23 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 113.25
BMY's PE Ratio without NRI is ranked higher than
54% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.28 vs. BMY: 113.25 )
Ranked among companies with meaningful PE Ratio without NRI only.
BMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.33  Med: 24.55 Max: 114.93
Current: 113.25
12.33
114.93
Price-to-Owner-Earnings 30.03
BMY's Price-to-Owner-Earnings is ranked higher than
66% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.28 vs. BMY: 30.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.57  Med: 23.91 Max: 413.04
Current: 30.03
3.57
413.04
PB Ratio 9.40
BMY's PB Ratio is ranked lower than
81% of the 825 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. BMY: 9.40 )
Ranked among companies with meaningful PB Ratio only.
BMY' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 5.06 Max: 9.54
Current: 9.4
2.46
9.54
PS Ratio 5.40
BMY's PS Ratio is ranked lower than
66% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. BMY: 5.40 )
Ranked among companies with meaningful PS Ratio only.
BMY' s PS Ratio Range Over the Past 10 Years
Min: 1.62  Med: 3.44 Max: 7.25
Current: 5.4
1.62
7.25
Price-to-Free-Cash-Flow 26.56
BMY's Price-to-Free-Cash-Flow is ranked higher than
51% of the 217 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.63 vs. BMY: 26.56 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.45  Med: 20.06 Max: 375.94
Current: 26.56
7.45
375.94
Price-to-Operating-Cash-Flow 21.26
BMY's Price-to-Operating-Cash-Flow is ranked lower than
51% of the 294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.74 vs. BMY: 21.26 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.96  Med: 14.73 Max: 97.02
Current: 21.26
6.96
97.02
EV-to-EBIT 21.06
BMY's EV-to-EBIT is ranked higher than
53% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.21 vs. BMY: 21.06 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 16.35 Max: 126.7
Current: 21.06
6.2
126.7
EV-to-EBITDA 18.34
BMY's EV-to-EBITDA is ranked higher than
51% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.57 vs. BMY: 18.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 14.3 Max: 57.3
Current: 18.34
5.5
57.3
EV-to-Revenue 5.40
BMY's EV-to-Revenue is ranked lower than
65% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. BMY: 5.40 )
Ranked among companies with meaningful EV-to-Revenue only.
BMY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.6 Max: 7.4
Current: 5.4
1.6
7.4
PEG Ratio 7.87
BMY's PEG Ratio is ranked lower than
99.99% of the 313 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. BMY: 7.87 )
Ranked among companies with meaningful PEG Ratio only.
BMY' s PEG Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.32 Max: 84
Current: 7.87
0.7
84
Shiller PE Ratio 31.14
BMY's Shiller PE Ratio is ranked higher than
64% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.75 vs. BMY: 31.14 )
Ranked among companies with meaningful Shiller PE Ratio only.
BMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.83  Med: 17.97 Max: 36.36
Current: 31.14
10.83
36.36
Current Ratio 1.55
BMY's Current Ratio is ranked lower than
69% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. BMY: 1.55 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.6 Max: 2.21
Current: 1.55
1.15
2.21
Quick Ratio 1.43
BMY's Quick Ratio is ranked lower than
61% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. BMY: 1.43 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.41 Max: 1.99
Current: 1.43
0.95
1.99
Days Inventory 86.53
BMY's Days Inventory is ranked higher than
61% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.37 vs. BMY: 86.53 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 72.42  Med: 116.62 Max: 141.93
Current: 86.53
72.42
141.93
Days Sales Outstanding 76.37
BMY's Days Sales Outstanding is ranked lower than
51% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.67 vs. BMY: 76.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.65 Max: 76.37
Current: 76.37
35.38
76.37
Days Payable 135.27
BMY's Days Payable is ranked higher than
69% of the 630 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.56 vs. BMY: 135.27 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 105.39  Med: 141.65 Max: 230.86
Current: 135.27
105.39
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.31
BMY's Dividend Yield % is ranked higher than
71% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. BMY: 2.31 )
Ranked among companies with meaningful Dividend Yield % only.
BMY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 3.82 Max: 7.07
Current: 2.31
1.99
7.07
Dividend Payout Ratio 2.57
BMY's Dividend Payout Ratio is ranked lower than
78% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. BMY: 2.57 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.92 Max: 2.57
Current: 2.57
0.58
2.57
3-Year Dividend Growth Rate 2.70
BMY's 3-Year Dividend Growth Rate is ranked lower than
61% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. BMY: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3 Max: 12.3
Current: 2.7
0
12.3
Forward Dividend Yield % 2.35
BMY's Forward Dividend Yield % is ranked higher than
67% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.77 vs. BMY: 2.35 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.64
BMY's 5-Year Yield-on-Cost % is ranked higher than
67% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. BMY: 2.64 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.28  Med: 4.39 Max: 8.12
Current: 2.64
2.28
8.12
3-Year Average Share Buyback Ratio 0.60
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.00 vs. BMY: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: 0.6
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 30.11
BMY's Price-to-Tangible-Book is ranked lower than
89% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. BMY: 30.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.75  Med: 12.28 Max: 53.46
Current: 30.11
4.75
53.46
Price-to-Intrinsic-Value-Projected-FCF 2.78
BMY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
52% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. BMY: 2.78 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.13  Med: 2 Max: 4.89
Current: 2.78
1.13
4.89
Price-to-Median-PS-Value 1.57
BMY's Price-to-Median-PS-Value is ranked lower than
72% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.05 vs. BMY: 1.57 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.68  Med: 0.89 Max: 2.5
Current: 1.57
0.68
2.5
Price-to-Peter-Lynch-Fair-Value 5.31
BMY's Price-to-Peter-Lynch-Fair-Value is ranked higher than
52% of the 190 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. BMY: 5.31 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.77  Med: 2.21 Max: 7.81
Current: 5.31
0.77
7.81
Price-to-Graham-Number 12.20
BMY's Price-to-Graham-Number is ranked lower than
83% of the 456 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.96 vs. BMY: 12.20 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.79  Med: 3.47 Max: 12.2
Current: 12.2
1.79
12.2
Earnings Yield (Greenblatt) % 4.75
BMY's Earnings Yield (Greenblatt) % is ranked higher than
68% of the 868 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.18 vs. BMY: 4.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.1 Max: 16.1
Current: 4.75
0.8
16.1
Forward Rate of Return (Yacktman) % 23.63
BMY's Forward Rate of Return (Yacktman) % is ranked higher than
72% of the 411 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.51 vs. BMY: 23.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15  Med: 4 Max: 26.7
Current: 23.63
-15
26.7

More Statistics

Revenue (TTM) (Mil) $20,776.00
EPS (TTM) $ 0.60
Beta1.05
Short Percentage of Float0.75%
52-Week Range $51.56 - 70.05
Shares Outstanding (Mil)1,632.58

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 21,687 23,344 24,525
EBIT (Mil $) 6,123 6,732 7,254
EBITDA (Mil $) 6,730 7,528 8,121
EPS ($) 3.24 3.76 4.40
EPS without NRI ($) 3.24 3.76 4.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.85%
Dividends per Share ($) 1.67 1.65 1.70

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}